<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02438072</url>
  </required_header>
  <id_info>
    <org_study_id>CER-14051</org_study_id>
    <nct_id>NCT02438072</nct_id>
  </id_info>
  <brief_title>Drug Metabolism and Antidepressant</brief_title>
  <acronym>METADEP</acronym>
  <official_title>Cocktail Phenotypic Approach to Explore Antidepressant Pharmacokinetic Variability: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose here to explore systematically the association between drug-metabolizing enzymes
      activity assessed by a phenotypical approach and antidepressant plasma concentration,
      efficacy and tolerance in the clinical setting. During one year, patients receiving
      antidepressant will be included in tis prospective clinical, naturalistic and descriptive
      pilot study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Objectives To describe drug metabolism variability in depressive patients using a
           phenotypic approach

        -  Study design Prospective, clinical, naturalistic, descriptive study During a
           consultation with their clinician, depressive patients will receive information.

      During the visit V0 with an investigator: patients will be included:

        -  Verification of inclusion and non inclusion criteria

        -  Reminder participation conditions

        -  Inclusion, signature of consent

        -  Collection of clinical and demographic features Between V0 and V1, for patients with
           change in antidepressant therapy, will take place telephone interviews every two weeks,
           conducted by the clinician to evaluate treatment depression response (tolerance and
           efficacy)

      During the visit V1, will take place:

        -  Phenotypic study

        -  Genetic study

        -  Dosage of current antidepressant drug

        -  Clinical evaluation: efficacy and tolerance

             -  Number of patients During one year, the protocol will be proposed to all patients
                with depression and decision of change in antidepressant therapy, and all patients
                with stability od prescription since almost 6 weeks. The inclusion of approximately
                100 patients is expected.

             -  Name of the finished product Zyban®, Froben®, Antra®, Bexine®, Dormicum® Telfast®

             -  Name of the active substance Omeprazole (10 mg, A02BC01) Caffeine (50 mg, N06BC01)
                Flurbiprofen (10 mg, M01AE09) Dextromethorphan (10 mg, R05DA09) Midazolam (1 mg,
                N05CD08) Fexofenadine (25mg, R06AX26 ) Bupropion (20 mg, N06AX12)

             -  Duration of treatment One time during the study, one day (Visit 1)

             -  Time plan of research -Duration for the patient: The study will stop when the
                patient has performed the V1 study Minimal delay between V0 and V1: 6 weeks (5-7
                weeks) : for patient with decision to change the treatment, 5 days for patients
                with stability of treatment since almost 6 weeks.

      Maximal delay of participation for the patient: 4 months even when V1 was not performed

      -Overall duration of inclusion: one year Maximal overall duration of the study: 12 months+4
      months= 16 months Maximal duration for the analytical study since the beginning of the study=
      16 months+6 months: 22 months.

      Maximal delay for communication of the results: 2 years after the beginning of the study
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CYP1A2 activity</measure>
    <time_frame>&gt;two hours after an oral intake of the cocktail probe drugs</time_frame>
    <description>paraxanthine/caffeine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CYP2B6 activity</measure>
    <time_frame>&gt;two hours after an oral intake of the cocktail probe drugs</time_frame>
    <description>4-hydroxybupropion/ bupropion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CYP2D6 activity</measure>
    <time_frame>&gt;two hours after an oral intake of the cocktail probe drugs</time_frame>
    <description>dextrorphan / dextromethorphan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CYP2C9 activity</measure>
    <time_frame>&gt;two hours after an oral intake of the cocktail probe drugs</time_frame>
    <description>4-hydroxyflurbiprofen/ flurbiprofen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CYP2C19 activity</measure>
    <time_frame>&gt;two, three and six hours after an oral intake of the cocktail probe drugs</time_frame>
    <description>5-hydroxyomeprazole/ omeprazole</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CYP3A4 activity</measure>
    <time_frame>&gt;two hours after an oral intake of the cocktail probe drugs</time_frame>
    <description>1-hydroxymidazolam/ midazolam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>P-gp activity</measure>
    <time_frame>&gt;two, three and six hours after an oral intake of the cocktail probe drugs</time_frame>
    <description>Limited sampling fexofenadine AUC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antidepressant Concentration</measure>
    <time_frame>almost 6 weeks after the last treatment change</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidepressant tolerance</measure>
    <time_frame>almost 6 weeks after the last treatment change</time_frame>
    <description>FISBER test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidepressant efficacy</measure>
    <time_frame>almost 6 weeks after the last treatment change</time_frame>
    <description>Tests: MADRS, Hamilton, QIDS-16</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Overall population</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole (10 mg, A02BC01)</intervention_name>
    <description>The cocktail of drug substrates will be given one time, one day during the study, to explore the activity of CYP 1A2, 2B6, 2C9, 2C19, 3A4, 2D6, and the P-gp</description>
    <arm_group_label>Overall population</arm_group_label>
    <other_name>Flurbiprofen (10 mg, M01AE09)</other_name>
    <other_name>Dextromethorphan (10 mg, R05DA09)</other_name>
    <other_name>Midazolam (1 mg, N05CD08)</other_name>
    <other_name>Fexofenadine (25mg, R06AX26 )</other_name>
    <other_name>Bupropion (20 mg, N06AX12)</other_name>
    <other_name>Caffeine (50 mg, N06BC01)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with clinical diagnosis of depression and decision to change antidepressant
             therapy (augmentation or switch) OR Patients with clinical diagnosis of depression and
             stability of prescription since almost 6 weeks

          2. Male and female aged from 18 to 70 years

          3. Volunteers to participate to the study

          4. Understanding of French language and able to give a written inform consent.

        Exclusion Criteria:

        Renal or hepatic impairment (Clearance below 60mL/min, AST or ALT over 3N) Sensitivity to
        any of the substrate drugs used ECG showing long QT interval (&gt;0.46sec) No antidepressant
        dosage available Current pregnancy or desire to get pregnant

        Criteria to perform V1 Sufficient compliance between V0 and V1 Six weeks period without
        change in antidepressant therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Celia Lloret-Linares, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux universitaires de Genève</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Celia Lloret-Linares, MD, PhD</last_name>
    <phone>0041 79 55 36 389</phone>
    <email>Celia.LloretLinares@hcuge.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Genève</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>celia Lloret-Linares, MD, PhD</last_name>
      <phone>0041 79 55 36 389</phone>
      <email>celia.LloretLinares@hcuge.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Bosilkovska M, Samer CF, Déglon J, Rebsamen M, Staub C, Dayer P, Walder B, Desmeules JA, Daali Y. Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots. Clin Pharmacol Ther. 2014 Sep;96(3):349-59. doi: 10.1038/clpt.2014.83. Epub 2014 Apr 10.</citation>
    <PMID>24722393</PMID>
  </reference>
  <results_reference>
    <citation>Hall-Flavin DK, Winner JG, Allen JD, Carhart JM, Proctor B, Snyder KA, Drews MS, Eisterhold LL, Geske J, Mrazek DA. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics. 2013 Oct;23(10):535-48. doi: 10.1097/FPC.0b013e3283649b9a.</citation>
    <PMID>24018772</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2015</study_first_submitted>
  <study_first_submitted_qc>May 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <last_update_submitted>May 5, 2015</last_update_submitted>
  <last_update_submitted_qc>May 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Celia Lloret-Linares</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>antidepressive agent</keyword>
  <keyword>drug metabolism</keyword>
  <keyword>CYP450</keyword>
  <keyword>P-glycoprotein</keyword>
  <keyword>Phenotypic study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Flurbiprofen</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
    <mesh_term>Fexofenadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

